The role of circulating, oxidized low-density lipoprotein and interleukin-6 levels in acute ischemic stroke considering the primary-vessel disease was investigated. The study consisted of 28 patients with acute ischemic stroke and 23 control subjects. Patients were subdivided into large-vessel (n = 12) and small-vessel (n =16) disease stroke groups according to the Trial of Org 10172 in Acute Stroke Treatment (TOAST) criteria. The means of oxidized low-density lipoprotein and interleukin-6 levels of patients with acute ischemic stroke were higher than controls (P < .01, P < .05). Mean oxidized low-density lipoprotein level was higher in the large-vessel disease group than in the small-vessel disease group (P < .01). The mean of inteleukin-6 levels was higher in the small-vessel disease group (P < .01). The results of the present study showed that oxidative stress promotes large-vessel disease rather than small-vessel disease stroke, and inflammation may play important an role in the development of small-vessel disease stroke.
Libby P., Ridker PM, Maseri A.Inflammation and atherosclerosis. Circulation. 2002;105:1135-1143.
2.
Fassbender K. , Bertsch T., Mielke O., et al. Adhesion molecules in cerebrovascular diseases. Evidence for an inflammatory endothelial activation in cerebral large-and small-vessel disease. Stroke. 1999 ;30:1647-1650.
3.
Castellanos M., Castillo J., Garcia MM, et al. Inflammation-mediated damage in progressing lacunar infarctions: a potential therapeutic target. Stroke . 2002;33:982-987.
4.
Fassbender K. , Rossol S., Kammer T., et al. Proinflammatory cytokines in serum of patients with acute cerebral ischemia: kinetics of secretion and relation to the extent of brain damage and outcome of disease. J Neurol Sci. 1994;122:135-139.
5.
Vila N., Castillo J., Dávalos A., et al. Proinflammatory cytokines and early neurological worsening in ischemic stroke. Stroke. 2000;31:2325-2329.
6.
Gorelick PB, Schneck M., Berglund LF, et al. Status of lipids as a risk factor for stroke. Neuroepidemiology. 1997;16:107-115.
Adams HP, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. Stroke. 1993;24:35-41.
9.
Uno M., Harada M., Takimoto O., et al. Elevation of plasma oxidized LDL in acute stroke patients is associated with ischemic lesions depicted by DWI and predictive of infarct enlargement. Neurol Res. 2005;27:94-102.
10.
Shie FS, Neely MD, Maezawa I., et al. Oxidized low-density lipoprotein is present in astrocytes surrounding cerebral infarcts and stimulates astrocyte interleukin-6 secretion. Am J Pathol. 2004;164:1173-1181.
11.
Ehara S., Ueda M., Naruko T., et al. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation. 2001;103:1955-1960.
12.
Toshima S., Hasegawa A., Kurabayashi M., et al. Circulating oxidized low density lipoprotein levels: a biochemical risk marker for coronary heart disease. Arterioscler Thromb Vasc Biol. 2000;20:2243-2247.
13.
Polidori MC , Frei B., Cherubini A., et al. Increased plasma levels of lipid hydroperoxides in patients with ischemic stroke. Free Radic Biol Med. 1998;25:561-567.
14.
Uno M., Kitazato KT, Nishi K., et al. Raised plasma oxidised LDL in acute cerebral infarction. J Neurol Neurosurg Psychiatry. 2003;74:312-316.
15.
Taddei S., Virdis A., Ghiadoni L., et al. Age related reduction of NO availability and oxidative stress in humans. Hypertension. 2001;38:274-279.
16.
Leinonen JS , Ahonen JP,Lonnrot K., et al. Low plasma antioxidant activity is associated with high lesion volume and neurological impairment in stroke. Stroke. 2000;31:33-39.
17.
Waje-Andreassen U., Krakenes J., Ulvestad E., et al. IL-6: an early marker for outcome in acute ischemic stroke. Acta Neurol Scand. 2005;111:360-365.
18.
Maier W., Altwegg LA, Corti R., et al. Inflammatory markers at the site of ruptured plaque in acute myocardial infarction: locally increased interleukin-6 and serum amyloid A but decreased C-reactive protein. Circulation. 2005; 111:1355-1361.
19.
Beneviste ENInflammatory cytokines within the central nervous system: sources, function, and mechanism of action. Am J Physiol Cell Physiol. 1992;263:C1-16.
20.
Tarkowski E., Rosengren L., Blomstrand C., et al. Early intrathecal production of interleukin-6 predicts the size of brain lesion in stroke. Stroke. 1995;26:1393-1398.
21.
Sei Y., Vitkovic L., Yokoyama MMCytokines in the central nervous system: regulatory roles in neuronal function, cell death and repair. Neuroimmunomodulation. 1995;2:121-133.
22.
Takei A., Huang Y., Lopes-Virella MFExpression of adhesion molecules by human endothelial cells exposed to oxidized low-density lipoprotein. Influences of degree of oxidation and location of oxidized LDL. Atherosclerosis. 2001;154:79-86.
23.
Hulthe J., Fagerberg B.Circulating oxidized LDL is associated with subclinical atherosclerosis development and inflammatory cytokines (AIR Study). Arterioscler Thromb Vasc Biol. 2002;22:1162-1167.
24.
Niemann-Jonsson A., Dimayuga P., Jovinge S., et al. Accumulation of LDL in rat arteries is associated with activation of tumor necrosis factor-alpha expression. Arterioscler Thromb Vasc Biol. 2000;20:2205-2211.
25.
Massy ZA, Kim Y., Guijarro C., et al. Low-density lipoprotein-induced expression of interleukin-6, a marker of human mesangial cell inflammation: effects of oxidation and modulation by lovastatin. Biochem Biophys Res Commun. 2000;267:536-540.
